特发性炎性肌病相关间质性肺疾病动物模型概述

doi:10.11958/20231796

天津医药 ›› 2024, Vol. 52 ›› Issue (7): 709-713.doi: 10.11958/20231796

• 专题研究·结缔组织病-间质性肺病/肺动脉高压（主编魏蔚） • 上一篇下一篇

特发性炎性肌病相关间质性肺疾病动物模型概述

刘智超¹(), 李霄鹤¹, 周红刚¹, 张娜²^,^∆()

1 南开大学药学院，天津市分子药物研究重点实验室（邮编300353）
2 天津医科大学总医院风湿免疫科，天津市免疫系统疾病临床医学研究中心

收稿日期:2023-11-20 修回日期:2024-01-21 出版日期:2024-07-15 发布日期:2024-07-11
通讯作者: ^∆E-mail：lunazhang22@hotmail.com
作者简介:刘智超（1998），男，硕士在读，主要从事肺纤维化和结缔组织病相关间质性肺病方面研究。E-mail：13156371830@163.com
基金资助:
国家自然科学基金资助项目(82270069)

Overview of animal models of idiopathic inflammatory myopathy-associated interstitial lung disease

LIU Zhichao¹(), LI Xiaohe¹, ZHOU Honggang¹, ZHANG Na²^,^∆()

1 College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China
2 Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin Clinical Medical Research Center for Immune System Diseases

Received:2023-11-20 Revised:2024-01-21 Published:2024-07-15 Online:2024-07-11
Contact: ^∆E-mail：lunazhang22@hotmail.com

刘智超, 李霄鹤, 周红刚, 张娜. 特发性炎性肌病相关间质性肺疾病动物模型概述[J]. 天津医药, 2024, 52(7): 709-713.

LIU Zhichao, LI Xiaohe, ZHOU Honggang, ZHANG Na. Overview of animal models of idiopathic inflammatory myopathy-associated interstitial lung disease[J]. Tianjin Medical Journal, 2024, 52(7): 709-713.

摘要/Abstract

摘要：

特发性炎性肌病（IIM）是一种病因不明的、以四肢近端肌肉受累和慢性炎症为突出表现的异质性自身免疫性疾病，可累及多个系统，其中间质性肺病（ILD）是IIM最常见的呼吸系统受累表现。该文总结了当前IIM动物模型及相关ILD模型构建方法，为后续IIM-ILD模型构建及研究提供参考。

关键词: 多发性肌炎, 肺疾病, 间质性, 模型, 动物, 综述

Abstract:

Idiopathic inflammatory myopathy (IIM) is a heterogeneous autoimmune disease of unknown etiology characterized by proximal limb muscle involvement and chronic inflammation. Multiple systems may be involved, with interstitial lung disease (ILD) being the most common manifestation of respiratory system involvement in IIM. This article summarizes the current methods of myositis animal models and myositis-associated ILD model construction methods, so as to provide reference for the subsequent construction and research of IIM-ILD models.

Key words: polymyositis, lung diseases, interstitial, models, animal, review

中图分类号:

R966

参考文献 31

[1]	LUNDBERG I E, FUJIMOTO M, VENCOVSKY J, et al. Idiopathic inflammatory myopathies[J]. Nat Rev Dis Primers, 2021, 7(1):86. doi:10.1038/s41572-021-00321-x.
[2]	FINDLAY A R, GOYAL N A, MOZAFFAR T. An overview of polymyositis and dermatomyositis[J]. Muscle Nerve, 2015, 51(5):638-656. doi:10.1002/mus.24566.
[3]	MAHLER M, MILLER F W, FRITZLER M J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review[J]. Autoimmun Rev, 2014, 13(4-5):367-371. doi:10.1016/j.autrev.2014.01.022.
[4]	SCHMIDT J. Current classification and management of inflammatory myopathies[J]. J Neuromuscul Dis, 2018, 5(2):109-129. doi:10.3233/JND-180308.
[5]	LUNDBERG I E, TJÄRNLUND A, BOTTAI M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Ann Rheum Dis, 2017, 76(12):1955-1964. doi:10.1136/annrheumdis-2017-211468.
[6]	YE S, CHEN X X, LU X Y, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease:a retrospective cohort study[J]. Clin Rheumatol, 2007, 26(10):1647-1654. doi:10.1007/s10067-007-0562-9.
[7]	DAWKINS R L. Experimental myositis associated with hypersensitivity to muscle[J]. J Pathol Bacteriol, 1965, 90(2):619-625. doi:10.1002/path.1700900231.
[8]	MATSUBARA S, OKUMURA S. Experimental autoimmune myositis in SJL/J mice produced by immunization with syngeneic myosin B fraction. Transfer by both immunoglobulin G and T cells[J]. J Neurol Sci, 1996, 144(1/2):171-175. doi:10.1016/s0022-510x(96)00223-7.
[9]	KANG J, ZHANG H Y, FENG G D, et al. Development of an improved animal model of experimental autoimmune myositis[J]. Int J Clin Exp Pathol, 2015, 8(11):14457-14464.
[10]	SUGIHARA T, SEKINE C, NAKAE T, et al. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis[J]. Arthritis Rheum, 2007, 56(4):1304-1314. doi:10.1002/art.22521.
[11]	ZHANG S, JIA X, ZHANG Q, et al. Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway[J]. J Cell Mol Med, 2020, 24(2):1658-1669. doi:10.1111/jcmm.14858.
[12]	LAYOUN H, HAJAL J, SALIBA Y, et al. Pirfenidone mitigates TGF-β1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model[J]. Cytokine, 2022,154:155899. doi:10.1016/j.cyto.2022.155899.
[13]	KOHYAMA K, MATSUMOTO Y. C-protein in the skeletal muscle induces severe autoimmune polymyositis in Lewis rats[J]. J Neuroimmunol, 1999, 98(2):130-135. doi:10.1016/s0165-5728(99)00087-9.
[14]	KAMIYA M, MIZOGUCHI F, YASUDA S. Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis[J]. J Cachexia Sarcopenia Muscle, 2022, 13(4):2118-2131. doi:10.1002/jcsm.13025.
[15]	BOWLES N E, DUBOWITZ V, SEWRY C A, et al. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection[J]. Lancet, 1987, 1(8540):1004-1007. doi:10.1016/s0140-6736(87)92271-9.
[16]	TARIQ N, KYRIAKOPOULOS C. Group B Coxsackie Virus. In:StatPearls. Treasure Island(FL): StatPearls Publishing, 2023.
[17]	AFZALI A M, RUCK T, WIENDL H, et al. Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?[J]. Autoimmun Rev, 2017, 16(5):478-494. doi:10.1016/j.autrev.2017.03.001.
[18]	NALBANDIAN A, LLEWELLYN K J, BADADANI M, et al. A progressive translational mouse model of human valosin-containing protein disease:the VCP(R155H/+) mouse[J]. Muscle Nerve, 2013, 47(2):260-270. doi:10.1002/mus.23522.
[19]	KINDER T B, HEIER C R, TULLY C B, et al. Muscle weakness in myositis: microRNA-mediated dystrophin reduction in a myositis mouse model and human muscle biopsies[J]. Arthritis Rheumatol, 2020, 72(7):1170-1183. doi:10.1002/art.41215.
[20]	CHAKRABARTI S, KOBAYASHI K S, FLAVELL R A, et al. Impaired membrane resealing and autoimmune myositis in synaptotagmin VII-deficient mice[J]. J Cell Biol, 2003, 162(4):543-549. doi:10.1083/jcb.200305131.
[21]	OKIYAMA N, ICHIMURA Y, SHOBO M, et al. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis[J]. Ann Rheum Dis, 2021, 80(9):1201-1208. doi:10.1136/annrheumdis-2020-218661.
[22]	KATSUMATA Y, RIDGWAY W M, ORISS T, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation[J]. J Autoimmun, 2007, 29(2/3):174-186. doi:10.1016/j.jaut.2007.07.005.
[23]	SOEJIMA M, KANG E H, GU X, et al. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis[J]. Arthritis Rheum, 2011, 63(2):479-487. doi:10.1002/art.30113.
[24]	AYILYA B L, BALDE A, RAMYA M, et al. Insights on the mechanism of bleomycin to induce lung injury and associated in vivo models:A review[J]. Int Immunopharmacol, 2023,121:110493. doi:10.1016/j.intimp.2023.110493.
[25]	WILFONG E M, AGGARWAL R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease[J]. Ther Adv Musculoskelet Dis, 2021,13:1759720X211060907. doi:10.1177/1759720X211060907.
[26]	GONO T, KANEKO H, KAWAGUCHI Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease[J]. Rheumatology (Oxford), 2014, 53(12):2196-2203. doi:10.1093/rheumatology/keu258.
[27]	ZHANG L, FU X H, YU Y, et al. Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis[J]. Lab Invest, 2015, 95(1):65-77. doi:10.1038/labinvest.2014.135.
[28]	KOSLOWSKI R, KNOCH K, KUHLISCH E, et al. Cathepsins in bleomycin-induced lung injury in rat[J]. Eur Respir J, 2003, 22(3):427-435. doi:10.1183/09031936.03.00112903.
[29]	GRAMAGLIA I, JEMBER A, PIPPIG S D, et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion[J]. J Immunol, 2000, 165(6):3043-3050. doi:10.4049/jimmunol.165.6.3043.
[30]	ZAIZEN Y, OKAMOTO M, AZUMA K, et al. Enhanced immune complex formation in the lungs of patients with dermatomyositis[J]. Respir Res, 2023, 24(1):86. doi:10.1186/s12931-023-02362-0.
[31]	HOSHINO T, KATO S, OKA N, et al. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13[J]. Am J Respir Crit Care Med, 2007, 176(1):49-62. doi:10.1164/rccm.200603-316OC.

特发性炎性肌病相关间质性肺疾病动物模型概述

Overview of animal models of idiopathic inflammatory myopathy-associated interstitial lung disease

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张兰英, 张福安, 刘茂茂, 陈杰, 周健, 刘钰婷, 欧阳瑶. CD1a⁺和CD83⁺树突状细胞在COPD小鼠肺组织中的分布及意义[J]. 天津医药, 2024, 52(9): 913-916.
[2]	王远珍, 魏红艳, 常丽仙, 张映媛, 刘春云, 刘立. 原发性肝癌干预前并发肺部感染风险预测模型的建立与验证[J]. 天津医药, 2024, 52(9): 940-945.
[3]	林峰, 陈铃雄, 刘羽, 张旭明, 尹志达, 林坛辉, 刘尊荣. 紫杉醇涂层球囊治疗2型糖尿病膝下动脉严重病变患者发生远期再狭窄预测模型的构建[J]. 天津医药, 2024, 52(8): 830-834.
[4]	郭振江, 赵光远, 杜立强, 刘防震. 近端胃癌上切缘阳性术前列线图预测模型的建立和验证[J]. 天津医药, 2024, 52(8): 845-849.
[5]	李冬生, 秦艺榕, 乔曼, 迟航, 崔青敏, 李晓秋. 清咳平喘颗粒对COPD急性加重期的临床疗效[J]. 天津医药, 2024, 52(8): 854-857.
[6]	李梦涛, 王迁. 结缔组织病相关间质性肺病：从发病机制研究到“双达标”治疗策略[J]. 天津医药, 2024, 52(7): 673-678.
[7]	张国华, 张令令, 高兰, 罗俊丽, 申雅文, 刘磊, 王玉华. 结缔组织病相关间质性肺病合并肺癌16例临床分析[J]. 天津医药, 2024, 52(7): 687-690.
[8]	尹韦玉, 廖红丽, 刘媛. SS相关抗体在特发性炎症性肌病及其相关间质性肺炎中的临床意义[J]. 天津医药, 2024, 52(7): 695-700.
[9]	罗宴冉, 史晓飞, 韩磊, 张贝, 文路遥. 皮肌炎自身抗体在间质性肺病中的研究进展[J]. 天津医药, 2024, 52(7): 704-708.
[10]	王敏, 王龙胜, 陈磊. 骨质疏松症患者腰椎骨折预测模型的构建[J]. 天津医药, 2024, 52(7): 766-769.
[11]	王娴, 刘霞明, 陈曼玉, 赵君, 王立东. 基于机器学习对2型糖尿病肾病预测模型的构建及验证[J]. 天津医药, 2024, 52(7): 775-780.
[12]	蒋韬, 程红艳, 吴琼. 棕矢车菊素调节SDF-1α/CXCR4信号通路对妊娠糖尿病大鼠炎症反应的影响[J]. 天津医药, 2024, 52(6): 594-598.
[13]	赵术彤, 丁运, 李月川, 赵晓赟, 耿华, 徐美林. 轻度慢性阻塞性肺疾病的病理特征及其与炎性因子的相关性[J]. 天津医药, 2024, 52(6): 643-647.
[14]	王灵, 龙登炎. 重症监护病房获得性衰弱风险预测模型的构建[J]. 天津医药, 2024, 52(5): 486-489.
[15]	吴纪昆, 徐榕笛, 许景涵, 王乐, 丛洪良. 6种常见模型评分对NSTEMI患者远期预后预测价值的验证和比较[J]. 天津医药, 2024, 52(5): 541-547.